PDF) Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial
May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) - CLL Society
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Fixed Duration Venetoclax + Obinutuzumab - CLL14 Trial Update - CLL Pharmacist
Fixed Duration Venetoclax + Obinutuzumab - CLL14 Trial Update - CLL Pharmacist
Impact of High-Risk Genomic Features in Chronic Lymphocytic Leukaemia
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. - Abstract - Europe PMC
Practical Guidelines on Optimizing CLL Care in the Era of Molecular Therapies - Optimizing CLL Care - Module - Optimizing CLL Care - Oncology - Clinical Care Options
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study | Leukemia
CLL14: Venetoclax plus obinutuzumab for CLL | VJHemOnc
Design of the CLL14 study. CLL = chronic lymphocytic leukemia; CIRS =... | Download Scientific Diagram
Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia - ScienceDirect
PDF) Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial
Practical Guidelines on Optimizing CLL Care in the Era of Molecular Therapies - Optimizing CLL Care - Module - Optimizing CLL Care - Oncology - Clinical Care Options
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study | Journal of Clinical Oncology
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL
Practical Guidelines on Optimizing CLL Care in the Era of Molecular Therapies - Optimizing CLL Care - Module - Optimizing CLL Care - Oncology - Clinical Care Options
Lymphoma Hub on Twitter: "#LLMCongress2021 | ⏰Time for an update on #CLL14 Jennifer R. Brown @DanaFarber gives us an update on the phase 3 trial evaluating fixed duration (one year) venetoclax +
Frontiers | Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges | Oncology
VENCLEXTA® (venetoclax tablets) | CLL14 & MURANO Clinical Trial Study Designs
Comparison between Time-Limited,Venetoclax-Based and Continuous Bruton Thyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL):a Systematic Review and Network Meta-Analysis - ScienceDirect
VENCLEXTA® (venetoclax tablets) | CLL14 & MURANO Clinical Trial Study Designs
